Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer

Michael J. Boeckh,1 Ann M. Arvin,2 Kathleen M. Mullane,3 Luis H. Camacho,4 Drew J. Winston,3 Vicki A. Morrison,3 Kimberly Hurtado,7 Jessie Durand Hall,1 Lei Pang,7 Shu-Chih Su,7 Susan S. Kaplan,7 Paula W. Annunziato,7 and Zoran Popmihajlov7; on behalf of the V212 Protocol 001 Trial Group and V212 Protocol 011 Trial Group*

1Vaccine and Infectious Disease & Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, 2Department of Medicine, University of Chicago, Chicago, Illinois, USA, 3Medical Oncology, Oncology Consultants, Houston, Texas, USA, 4Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA, 5Hematology Oncology Division, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA, 6Hematology Oncology Division, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA, 7Merck & Co., Inc., Kenilworth, New Jersey, USA

Background. In phase 3 trials, inactivated varicella zoster virus (VZV) vaccine (ZV\textsubscript{IN}) was well tolerated and efficacious against herpes zoster (HZ) in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and patients with solid tumor malignancies receiving chemotherapy (STMc) but did not reduce HZ incidence in patients with hematologic malignancies (HMs). Here, we describe ZV\textsubscript{IN} immunogenicity from these studies.

Methods. Patients were randomized to ZV\textsubscript{IN} or placebo (4 doses). Immunogenicity was assessed by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and VZV interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in patients receiving all 4 doses without developing HZ at the time of blood sampling.

Results. Estimated geometric mean fold rise ratios (ZV\textsubscript{IN}/placebo) by gpELISA and IFN-γ ELISPOT ~28 days post–dose 4 were 2.02 (95% confidence interval [CI], 1.53–2.67) and 5.41 (95% CI, 3.60–8.12) in auto-HSCT recipients; 1.88 (95% CI, 1.79–1.98) and 2.10 (95% CI, 1.69–2.62) in patients with STMc; and not assessed and 2.35 (95% CI, 1.81–3.05) in patients with HM.

Conclusions. ZV\textsubscript{IN} immunogenicity was directionally consistent with clinical efficacy in auto-HSCT recipients and patients with STMc even though HZ protection and VZV immunity were not statistically correlated. Despite a lack of clinical efficacy in patients with HM, ZV\textsubscript{IN} immunogenicity was observed in this population. Immunological results did not predict vaccine efficacy in these 3 populations.

Clinical trial registration. NCT01229267, NCT01254630.

Keywords. cell-mediated immunity; humoral immunity; immunocompromised adults; immunogenicity; inactivated zoster vaccine.

Cell-mediated immunity plays a critical role in the containment of varicella zoster virus (VZV), preventing the reactivation of VZV and subsequent onset of herpes zoster (HZ) [1]. Immunocompromised individuals, such as patients who have undergone autologous hematopoietic stem cell transplant (auto-HSCT) or patients with malignancies, are at ~3–18-fold increased risk of HZ infection compared with immunocompetent patients, depending on the nature of the underlying condition [2–6]. The reported incidence of HZ in auto-HSCT recipients, despite antiviral prophylaxis, ranges from 62 of 1000 person-years (PYs), based on a large retrospective analysis [4], to 92 of 1000 PYs, based on a recent phase 3 randomized clinical trial [7]. For patients with solid tumor malignancies receiving chemotherapy (STMc), reports of HZ incidence range from 15 of 1000 PYs [3] to 19 of 1000 PYs [8]. For patients with hematologic malignancies (HMs), HZ incidence is reported to be 31 of 1000 PYs [2, 6, 8]. In comparison, HZ incidence in the general adult population is 5 of 1000 PYs [9].

In immunocompromised patients such as these, HZ causes significant morbidity, including pain, post-herpetic neuralgia, HZ ophthalmicus, visceral organ involvement, hospitalization, and occasional mortality [10–13]. Additionally, secondary bacterial infection, such as streptococcal or staphylococcal superinfections, can complicate HZ rash and, although complete healing of HZ rash typically occurs within 2 to 4 weeks, pigmentation changes and scarring may be permanent [13, 14].

The live attenuated VZV vaccine is contraindicated in immunocompromised patients [15]; therefore, an inactivated VZV vaccine (ZV\textsubscript{IN}) was investigated as a preventive option for...
immunocompromised patients. Proof-of-concept studies and a phase 1 trial using a heat-treated ZV$_{in}$ demonstrated immunogenicity and safety in auto-HSCT recipients and patients with STMc or HM through 28 days post–dose 4 following a 4-dose regimen administered ~30 days apart [16–18]. Subsequently, phase 1 and 2 trials using ZV$_{in}$ inactivated by gamma irradiation confirmed immunogenicity and safety in patients with HM receiving anti-CD20 monoclonal antibodies and in adults with autoimmune disease receiving immunsuppressive therapy, respectively [19, 20].

Primary safety and efficacy results from 2 phase 3 trials (V212-001 and V212-011) demonstrated that ZV$_{in}$ was well tolerated, with the incidence of HZ and HZ-related complications significantly reduced in auto-HSCT recipients and patients with STMc but not in patients with HM [7, 8]. In auto-HSCT recipients, the estimated vaccine efficacy of ZV$_{in}$ against HZ (VE$_{HZ}$) was 63.8% (95% confidence interval [CI], 48.4%–74.6%) [7]; in patients with STMc, the estimated VE$_{HZ}$ was 63.6% (97.5% CI, 36.4%–79.1%) [8]. Immunogenicity was assessed as an exploratory end point in these 2 phase 3 trials, with the results presented here.

**METHODS**

**Trial Designs**

V212-001 (NCT01229267) and V212-011 (NCT01254630) were phase 3, randomized, double-blind, placebo-controlled multicenter trials that evaluated the safety, tolerability, efficacy, and immunogenicity of ZV$_{in}$ for the prevention of HZ and HZ-related complications in auto-HSCT recipients (V212-001) and in patients with STMc or HM (V212-011). V212-001 was conducted between December 2010 and December 2015; V212-011 was conducted between June 2011 and April 2017. Ethical approval was obtained from the institutional review board at each trial site, and written informed consent was obtained from each participant before trial entry. The V212-001 and V212-011 protocols have been previously described [7, 8]. The studies were conducted in accordance with the principles of Good Clinical Practice. Patients were monitored for clinical signs and symptoms of HZ and HZ-related complications through the entire trial period. HZ was diagnosed primarily by polymerase chain reaction [7, 8].

**Trial Population**

Trials included males and females aged 18 years or older with a history of varicella infection or seropositivity for VZV antibody. V212-001 included participants scheduled to receive auto-HSCT for treatment of lymphoma, other malignancies, or any nonmalignant conditions within 60 days of enrollment. The exclusion criteria in V212-001 included underlying malignancies other than Hodgkin lymphoma associated with >2 disease relapses, planned tandem transplantation, and intended antiviral prophylaxis for more than 6 months after transplantation. V212-011 included patients with STMc or HM who were not likely to undergo HSCT and who were receiving a cytotoxic or immunosuppressive chemotherapy regimen. Patients with HM who were ≥50 years of age and not in remission were eligible, regardless of whether they were receiving chemotherapy. Common exclusion criteria in both trials were history of HZ within 1 year of enrollment and prior or expected receipt of any VZV vaccine. The exclusion criteria in V212-011 included current/expected receipt of long-term (>4 weeks) antiviral prophylaxis against HSV, VZV, or CMV.

**Treatment Administration**

In these trials, patients were randomly allocated to receive gamma-irradiated ZV$_{in}$ or placebo, administered in a 4-dose regimen ~30 days apart [7, 8]. For more details on the vaccine, see the Supplementary Methods. Auto-HSCT recipients received dose 1 ~30 days (60 to 5 days) before HSCT. Doses 2 through 4 were administered 30, 60, and 90 days after HSCT. Both patients with STMc and patients with HM received dose 1 of ZV$_{in}$ or placebo at the time of enrollment (day 1). Doses 2 through 4 were administered ~30 days after each previous dose. Among patients receiving cyclic chemotherapy, dose 1 of ZV$_{in}$ or placebo was administered ~5 days before any chemotherapy dose in the cycle. Doses 2 through 4 were administered ~20 to 40 days after the previous dose of vaccine or placebo; specifically, ZV$_{in}$ or placebo had to be administered ~5 days before the upcoming chemotherapy dose. To complete the studies, patients had to have completed the studies’ close-out questionnaires at the end of the safety follow-up period; these were administered over the phone. In V212-011, the HM group was discontinued due to statistical evidence of futility shown at a planned interim analysis.

**Immunogenicity Measurements**

Immunogenicity analyses were exploratory (no prespecified statistical hypotheses were tested) and were conducted in the per-protocol immunogenicity population. In both trials, the per-protocol immunogenicity population included patients who received all 4 doses and did not have HZ before blood sampling. For patients who received treatments interfering with measurements of VZV-specific antibody response (including those receiving immunoglobulin therapy) or who received medications interfering with B-cell function, the measurements at corresponding time points and thereafter were excluded from the immunogenicity analysis conducted by glycoprotein enzyme-linked immunosorbent assay (gpELISA). Patients who received immunoglobulin therapies were included in the immunogenicity analysis conducted by VZV interferon (IFN)-γ enzyme-linked immunospot (IFN-γ ELISPOT) assay because they did not interfere with T-cell function.

VZV-specific antibody responses were measured by gpELISA assay [21] in auto-HSCT recipients and in patients
with STMc. This antibody assay was not conducted in patients with HM because the nature of the disease and treatments could have biased the test results, based on the results from previous phase 1 gpELISA data in patients with HM [17]. Cell-mediated immune responses were measured by VZV IFN-γ ELISPOT assay [22] in subsets of auto-HSCT recipients, patients with STMc, and patients with HM. The VZV ELISPOT assay detected IFN-γ-secreting cells from peripheral blood mononuclear cells stimulated with VZV before and after vaccination. For immune responses measured by gpELISA, end points were the GMT and geometric mean fold rise (GMFR). For immune responses measured by VZV IFN-γ ELISPOT assay, end points were geometric mean count (GMC) and GMFR.

In auto-HSCT recipients, blood samples for immunogenicity analyses were collected on day 1 (before dose 1), ~28 days (21–35 days) post–dose 3, ~28 days (28–60 days) post–dose 4, and annually post–dose 4 until the end of the trial. In patients with STMc and HM, blood samples for immunogenicity analyses were collected on day 1 (before dose 1) and ~28 days (28–60 days) post–dose 4. PPD Vaccines and Biologics, LLC (Wayne, PA, USA), performed the gpELISA on serum samples, and ViraCor-IBT Laboratories, Inc. (Lenexa, KS, USA), performed the IFN-γ ELISPOT assays on peripheral blood mononuclear cell samples.

Statistical Analyses
A linear mixed longitudinal model was used on the natural log-transformed antibody titers for the comparison of GMTs between ZVIN and placebo recipients across the time points after vaccination. This longitudinal regression approach allowed for comparison of postvaccination antibody titers between the groups, adjusting for prevaccination antibody titer in the presence of incomplete data [23]. The model incorporated treatment group, visit, age (for V212-001: <50 vs ≥50 years; for V212-011: continuous variable), and treatment group-by-visit interaction. The fold-differences between the ZVIN and placebo recipients and the corresponding 95% CIs at the visits were obtained from this model.

A Cox regression model was used for ZVIN and placebo recipients, with immune responses measured by gpELISA at prespecified time points as covariates, to evaluate the association between immune responses and risk of HZ. The GMT and GMFR were also summarized at these time points by treatment group and HZ outcome (patients who developed confirmed HZ during the trial vs patients who did not).

A time-varying Cox proportional hazards model was used to estimate the relationship between HZ occurrence and gpELISA titers among ZVIN and placebo recipients. The gpELISA titers were used as the time-dependent covariate to obtain a risk ratio for HZ per unit increase in the titer. Using the natural log-scale of GMC, analyses of the comparison of GMC between treatment groups and evaluation of the association between GMC and HZ risk were performed similarly to the analyses and evaluations for gpELISA.

RESULTS
Demographics
Overall, 1257 auto-HSCT recipients were randomized to ZVIN (n = 560) or placebo (n = 564) (Supplementary Figure 1) [7], 2712 patients with STMc were randomized to ZVIN (n = 1348) or placebo (n = 1364) (Supplementary Figure 2) [8], and 2573 patients with HM were randomized to ZVIN (n = 1288) or placebo (n = 1285) (Supplementary Figure 2) [8]. More than 80% of patients (auto-HSCT recipients, 83%; patients with STMc, 87%; patients with HM, 90%) received all 4 doses. More than 70% of patients in each treatment group were older than 50 years (auto-HSCT recipients, 72%; patients with STMc, 77%–78%; patients with HM, 82%–83%). Among auto-HSCT recipients and patients with HM, the majority were male (auto-HSCT recipients, 64%; patients with HM, 59%). In contrast, most patients with STMc were female (64%–65%).

The most common primary diagnoses were myeloma among auto-HSCT recipients, breast cancer among patients with STMc, and chronic lymphocytic leukemia among patients with HM (Supplementary Table 1) [7, 8]. The most common concomitant medications included systemic antibacterial agents in auto-HSCT recipients, antineoplastic agents in patients with STMc, and analgesics in patients with HM (Supplementary Table 1) [8].

VZV-Specific Antibody Response by Glycoprotein ELISA
The observed GMT values in the ZVIN and placebo groups at baseline and the time points examined in auto-HSCT recipients and patients with STMc are shown in Figure 1 [7, 8]. In auto-HSCT recipients, the estimated GMFR ratio (ZVIN/placebo) was 2.02 (95% CI, 1.53–2.67) at ~28 days post–dose 4, 1.30 (95% CI, 0.99–1.71) at 1 year post–dose 4, and 1.34 (95% CI, 0.95–1.87) at 2 years post–dose 4 (Table 1). At 1 and 2 years post–dose 4, estimated VZV antibody responses remained slightly elevated compared with baseline levels (Table 1). Similarly, in patients with STMc, the estimated GMFR ratio was 1.88 (95% CI, 1.79–1.98) at ~28 days post–dose 4 (Table 1).

VZV-Specific Cell-Mediated Response by IFN-γ Enzyme-Linked Immunospot Assay
The observed GMC values in the ZVIN and placebo groups at baseline and at time points examined in auto-HSCT recipients and patients with STMc and HM are shown in Figure 2 [7, 8]. In auto-HSCT recipients, the estimated GMFR ratio (ZVIN/placebo) was 5.41 (95% CI, 3.60–8.12) at ~28 days post–dose 4, 4.12 (95% CI, 2.62–6.47) at 1 year post–dose 4, and 3.32 (95%
CI, 1.90–5.82) at 2 years post-dose 4 (Table 2). ZV IN recipients achieved an estimated GMFR from a baseline value of 1.85 at ~28 days post-dose 4, which increased up to 3.32 at 2 years post-dose 4. In placebo recipients, the estimated GMC values at ~28 days post-dose 4 and at 1 year post-dose 4 were lower than baseline values, and only at the 2-year post-dose 4 time point were estimated GMC values comparable with baseline. In patients with STMc and HM, the estimated GMFR ratios (ZV IN / placebo) were 2.10 (95% CI, 1.69–2.62) and 2.35 (95% CI, 1.81–3.05), respectively, at ~28 days post-dose 4 (Table 2). Among ZV IN recipients at ~28 days post-dose 4, estimated GMC values were highest in patients with STMc and lowest in auto-HSCT recipients.

Association Between Immune Response and Risk of Herpes Zoster
Post-dose 4 gpELISA and VZV IFN-γ ELISPOT assay results were available for a small number of ZV IN recipients who subsequently developed HZ (Tables 3 and 4). Among auto-HSCT recipients who received ZV IN, gpELISA GMT values at ~28 days post-dose 4 were lower in the group that developed

![Figure 1. VZV-specific antibody observed response by gpELISA in auto-HSCT recipients and patients with STMc (per-protocol population). Abbreviations: auto-HSCT, autologous hematopoietic stem cell transplant; gpELISA, glycoprotein enzyme-linked immunosorbent assay; STMc, solid tumor malignancies receiving chemotherapy; ZV IN, inactivated varicella zoster.](image-url)
HZ than in the group that did not, although CIs were broad and overlapping (Table 3). In patients with STMc, GMT values at ~28 days post–dose 4 were generally similar among those who did and did not develop HZ (Table 3). For both the auto-HSCT recipients and patients with HM who received ZVIN, VZV IFN-γ ELISPOT assay GMC values at ~28 days post–dose 4 were lower in the group that developed HZ than the group that did not, albeit with overlapping CIs (Table 4). Surprisingly, patients with STMc who developed HZ had high VZV IFN-γ ELISPOT assay GMC values at ~28 days post–dose 4, which were higher than GMC values among patients with STMc who did not develop HZ (Table 4). A statistical correlation was not

---

**Table 2.** VZV-Specific Cell-Mediated Estimated Immune Response by IFN-γ ELISPOT Assay in Auto-HSCT Recipients, Patients With STMc, and Patients With HM (Per-Protocol Population)

|                      | IFN-γ ELISPOT Assay Count/10⁶ PBMCsa | ZVIN | Placebo | GMFR Fold Differenceb for ZVIN/Placebo (95% CI) |
|----------------------|-------------------------------------|------|---------|-----------------------------------------------|
| Auto-HSCT            |                                     |      |         |                                               |
| ~28 days post–dose 4 | Number of patients vaccinated: ZVIN, 186; placebo, 181 | 168  | 171     | 5.41 (3.60–8.12) |
|                      | GMC                                 | 62.3 | 11.5    |                                               |
|                      | GMFRc                               | 1.85 | 0.34    |                                               |
| 1 year post–dose 4   | Number of patients vaccinated: ZVIN, 232; placebo, 246 | 168  | 171     |                                               |
|                      | GMC                                 | 83.1 | 20.2    |                                               |
|                      | GMFRc                               | 2.47 | 0.60    |                                               |
| 2 years post–dose 4  | Number of patients vaccinated: ZVIN, 187; placebo, 247 | 168  | 171     |                                               |
|                      | GMC                                 | 111.6| 33.6    |                                               |
|                      | GMFRc                               | 3.32 | 1.00    |                                               |
| STMc                 |                                     |      |         |                                               |
| ~28 days post–dose 4 | Number of patients vaccinated: ZVIN, 199; placebo, 246 | 208  | 221     |                                               |
|                      | GMC                                 | 163.2| 776     |                                               |
|                      | GMFRc                               | 2.46 | 1.17    |                                               |
| HM                   |                                     |      |         |                                               |
| ~28 days post–dose 4 | Number of patients vaccinated: ZVIN, 199; placebo, 246 | 187  | 183     |                                               |
|                      | GMC                                 | 97.5 | 41.5    |                                               |
|                      | GMFRc                               | 2.22 | 0.94    | (1.81–3.05)                                   |

Abbreviations: auto-HSCT, autologous hematopoietic stem cell transplant; IFN-γ ELISPOT, interferon-γ enzyme-linked immunospot; GMC, geometric mean count; GMFR, geometric mean fold rise; HM, hematologic malignancies; No., number of patients contributing to the immunogenicity analysis; PBMCs, peripheral blood mononuclear cells; STMc, solid tumor malignancies receiving chemotherapy; ZVIN, inactivated varicella zoster.

*Results from the IFN-γ ELISPOT assay are expressed as the frequency of spot-forming cells per million PBMCs.

*Calculated based on longitudinal regression model adjusting for prevaccination immunogenicity level in the presence of incomplete data, with treatment group, visit, and treatment group-by-visit as covariates.

*From day 1.
found between HZ protection and VZV gpELISA response in auto-HSCT recipients and patients with STMc (Table 5). In addition, no correlation was found by VZV IFN-γ ELISPOT assay response among patients with STMc (Table 5).

DISCUSSION

Defects in T-cell immunity increase the risk for HZ [1]. The gpELISA [21], which measures T-cell-dependent antibody responses, was shown in clinical studies of zoster vaccine to correlate with protection against HZ in healthy adults aged 50 years and older [24, 25]. At the time the phase 3 studies of ZVIN were conducted, it was unknown if the same relationship between gpELISA and VEHZ would be seen in immunocompromised populations. Among auto-HSCT recipients, the estimated GMFR ratio between ZVIN and placebo at ~28 days post–dose 4 across different immunocompromised populations. Among auto-HSCT recipients, the estimated GMFR ratio between treatment groups remained high at 1 and 2 years post–dose 4 (4.12 and 3.32, respectively). These results were similar to those observed in auto-HSCT recipients, patients with STMc (n = 56), and patients with HM (n = 60) enrolled in V212-002 [17].

The immunogenicity findings of ZVIN described here are consistent with those observed with zoster vaccine live in a nonimmunocompromised patient population. In the zoster vaccine live shingles prevention study, conducted in 38,546 patients aged ≥60 years, cell-mediated immunity, assessed by IFN-γ ELISPOT, and humoral immunity, assessed by gpELISA, were significantly increased in patients receiving live attenuated VZV vaccine measured at 6 weeks after vaccination compared with those receiving placebo (IFN-γ ELISPOT: 70.1 vs 31.7 GMC; gpELISA: 471.3 vs 292.3 GMT), and the increase in cell-mediated immunity persisted for 3 years of follow-up [26]. Similarly, in the zoster vaccine live efficacy and safety trial, conducted in 22,439 patients 50–59 years of age, humoral immunity, assessed by gpELISA, was significantly increased, with a GMFR of 2.3 [27]. In both studies, a specific level for any immune response that was predictive of protection against HZ was not identified.
Patients Without Confirmed HZ

Placebo

Placebo

ZVIN

Those observed in patients with STMc in the ZVIN group who did not develop HZ. However, in this population that may have received chemotherapy after receiving 4 doses of ZVIN, measurement of immunity at ~28 days post–dose 4 may not accurately reflect immunity before the development of HZ. Waning of cell-mediated immunity due to chemotherapy could subsequently increase HZ risk, which is thought to depend on cell-mediated immunity at the time that latent VZV reactivates [1]. Interestingly, in patients with HM, positive VZV-specific cell-mediated responses measured by IFN-γ ELISPOT assay were observed in the ZVIN group but did not translate into ZVIN vaccine efficacy. These unexpected findings point to the importance of assessing vaccine clinical efficacy, as well as immunogenicity, to understand the protective potential of investigational HZ vaccines or established HZ vaccines administered to new patient populations. It is possible that immunogenicity measured by the assays reported here may not predict vaccine efficacy in certain immunocompromised patient populations or for all vaccines.

Long-term immunogenicity data assessed at 1 and 2 years post–dose 4 in auto-HSCT recipients revealed a decline in humoral immunity in the ZVIN group, while cell-mediated immunity remained sustained. VZV-specific antibody responses by gpELISA in placebo-treated auto-HSCT recipients at 1 to 3 years post–dose 4 were lower than baseline values, a phenomenon previously seen in phase 1 testing [17], due to the highly immunosuppressive nature of the transplantation procedure performed after the baseline time point. As expected, VZV-specific cell-mediated immunity in the placebo group improved over the 2-year follow-up period of this study, as immunity has been shown to be restored following auto-HSCT procedures [28]. ZVIN elicited higher cell-mediated responses compared with placebo up to the 2-year post–dose 4 time point.
Table 5. Statistical Analysis of Immunogenic Response as a Correlate of Protection Against HZ, Using Cox Model in Auto-HSCT Recipients (VZV gpELISA Response), Patients With STMc (VZV gpELISA Response and VZV IFN-γ ELISPOT Assay Response), and Patients With HM (VZV IFN-γ ELISPOT Assay Response) in the Per-Protocol Population

| gpELISA Units/mL | Auto-HSCT | STMc | HM |
|------------------|-----------|------|----|
|                  | Point Estimate HR (95% CI) | P Value | Point Estimate HR (95% CI) | P Value | Point Estimate HR (95% CI) | P Value |
| Vaccine effect on HZ without adjustment for VZV gpELISA | 0.360 (0.25–0.51) | <.001 | 0.364 (0.22–0.59) | <.0001 | — | — |
| Vaccine effect on HZ with adjustment for VZV gpELISA | 0.364 (0.24–0.56) | <.001 | 0.378 (0.23–0.63) | <.0002 | — | — |
| Effect of VZV gpELISA (log-scale) on the risk of HZ | 1.037 (0.90–1.20) | .613 | 0.957 (0.78–1.18) | .6796 | — | — |

| IFN-γ ELISPOT Assay Count/10^6 PBMCs | Auto-HSCT | STMc | HM |
|-------------------------------------|-----------|------|----|
|                                    | Point Estimate HR (95% CI) | P Value | Point Estimate HR (95% CI) | P Value | Point Estimate HR (95% CI) | P Value |
| Vaccine effect on HZ without adjustment for VZV IFN-γ ELISPOT assay | — | — | 0.364 (0.22–0.59) | <.0001 | 0.833 (0.59–1.18) | .3035 |
| Vaccine effect on HZ with adjustment for VZV IFN-γ ELISPOT assay | — | — | 0.376 (0.10–1.47) | 1.603 | 1.337 (0.38–4.76) | .6536 |
| Effect of VZV IFN-γ ELISPOT assay (log-scale) on the risk of HZ | 1.011 (0.63–1.61) | .9622 | 0.713 (0.54–0.94) | .0171 |

Abbreviations: auto-HSCT, autologous hematopoietic stem cell transplant; gpELISA, glycoprotein enzyme-linked immunosorbent assay; HM, hematologic malignancies; HZ, herpes zoster; IFN-γ ELISPOT, interferon-γ enzyme-linked immunospot; PBMCs, peripheral blood mononuclear cells; STMc, solid tumor malignancies receiving chemotherapy.

aResults for the gpELISA are reported as concentration of antibody in gpELISA units/mL.
bFor vaccine effect on HZ incidence, the treatment-by-immunogenicity response interaction was statistically significant (P = .049); this P value for the interaction was calculated based on the likelihood ratio test.
cComputed based on a Cox regression model that included time to HZ onset as the response variable and treatment group, age stratum, and expected duration of antiviral prophylaxis (for auto-HSCT recipients) as explanatory variables.
dComputed based on a Cox regression model that included time to HZ onset as the response variable and treatment group, age stratum, expected duration of antiviral prophylaxis (for auto-HSCT recipients), and the natural log-transformed VZV gpELISA as time-varying explanatory variables.
eResults from the IFN-γ ELISPOT assay are expressed as the frequency of spot-forming cells per million PBMCs.
fComputed based on a Cox regression model that included time to HZ onset as the response variable and treatment group, age stratum, and HM immunocompromised stratum (for patients with HM) as explanatory variables.
gComputed based on a Cox regression model that included time to HZ onset as the response variable and treatment group, age stratum, and HM as explanatory variables.
A limitation of the V212-011 trial is that humoral immunity and cell-mediated immunity were not measured at 1 year post-dose 4; therefore, long-term immunogenicity data in patients with STMc and HM are not available. Although these are the first large vaccine trials conducted in these patient groups, the number of patients enrolled in both the V212-001 and V212-011 trials who were eligible to be included in the immunogenicity analysis was small. This precluded a robust analysis of the association between immune response and the risk of HZ. In trial V212-001, most exclusions from the immunogenicity analyses were due to use of prohibited concomitant medications, as expected in this patient population. Another limitation is that the Cox proportional hazards model used for the immunogenicity analyses did not include postrandomization use of immunosuppression. One key difference of the transplant population studied in the current trial vs the trials in immunocompetent patients is the relatively high proportion of patients with “nonvalid assays” in the ELISPOT assay (37 of 188 ZV<sub>in</sub> recipients [20%] and 39 of 182 placebo recipients [21%]) (Supplementary Figure 1). The observed effect may be due to the high level of immunosuppression, which is a well-known phenomenon among transplant recipients [29–31].

In summary, these 2 phase 3 trials demonstrated that ZV<sub>in</sub> elicits cellular immune responses when measured by IFN-γ ELISPOT assay in the 3 immunocompromised populations examined: auto-HSCT recipients, patients with STMc, and patients with HM. Although our immunogenicity data are consistent with the ZV<sub>in</sub> clinical efficacy in HZ prevention in auto-HSCT recipients and patients with STMc, demonstrated in the same studies, the immunogenicity data we report in patients with HM did not translate into clinical efficacy in HZ prevention.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments
The authors acknowledge Erin H. Jensen for providing additional analyses. Medical writing support was provided by Francesca Balordi, PhD, and Deborah Roney of the Lockwood Group (Stamford, CT, USA), in accordance with Good Publication Practice (GPP3) guidelines, and was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Author contributions. In collaboration with a scientific advisory committee (Michael J. Boechk, MD; Ann Arvin, MD; Kathleen M. Mullen, DO; Luis H. Camacho, MD; Drew J. Winston, MD; Vicki A. Morrison, MD) and the investigators, the trials were designed, executed, and analyzed by some members of the Merck V212-001/V212-011 trial groups. The opinions expressed in the manuscript are those of the authors and do not necessarily reflect those of Merck & Co., Inc., Kenilworth, NJ, USA. All authors approved the final version of the manuscript.

Data sharing. The data sharing policy of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, including restrictions, is available at http://engagezone.msd.com/ds_documentation.php.

Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.

Financial support. This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Potential conflicts of interest. M.I.B. has received grants and personal fees from Chimerix, GlaxoSmithKline, Merck & Co., Inc., and Gilead Sciences. A.M.A. conducted this work as part of an outside consulting agreement with Merck & Co., Inc.; the work is not associated in any way with Stanford University (Stanford, CA, USA). A.M.A. also received personal fees from Merck & Co., Inc. K.M.M. received grants and personal fees from Astellas Pharma, Chimerix, GlaxoSmithKline, Merck & Co., Inc., and Scynexis and has received grants from SAGE Therapeutics and Shire. L.H.C. received speakers’ fees from Merck & Co., Inc. D.J.W. received research grants from Merck & Co., Inc., for this vaccine (V212) and for a letermovir CMV prophylactic study in patients who have undergone hematopoietic stem cell transplantation, as well as fees for being a member of the scientific advisory board for inactivated varicella zoster vaccine and CMV infection. V.A.M. has received speakers’ fees from Celsege, Genentech, Gilead, GlaxoSmithKline, and Pharmacyclics; has received other fees from Genentech and Pharmacyclics for advisor activities and from Celsege for being a member of the CLI Data Monitoring Committee; and is a member of the Scientific Advisory Committee for this vaccine (V212) for Merck & Co., Inc. K.H., J.D.H., L.P., S.-C.S., S.K.S., P.W.A., and Z.P. were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, during the conduct of this trial and may hold stock/ options in the company. Other than employees of Merck & Co., Inc., all authors have been investigators for the sponsor. Employees may hold stock and/or stock options in the company. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Chen SY, Suyaa JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection 2014; 42:325–34.
2. Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev 2013; 22:82–90.
3. Mao J, McPheeters JT, Finelli L. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study. Medicine (Baltimore) 2017; 96:e8746.
4. Mao J, McPheeters JT, Zhang D, et al. Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant. Curr Med Res Opin 2018; 34:741–9.
5. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med 2007; 23:615–32, vii–viii.
6. Yenikomshian MA, Guignard AP, Haguinet F, et al. The epidemiology of herpes zoster and its complications in Medicare cancer patients. BMC Infect Dis 2015; 15:106.
7. Winston DJ, Mullan KM, Carnely OA, et al. Inactivated varicella zoster vaccine in autologous hematopoietic stem-cell transplantation: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391:2116–27.
8. Mullan KM, Morrison VA, Camacho LH, et al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis 2019; 19:1001–12.
9. Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015; 15:302.
10. Ansaldo F, Trucchi C, Alcino C, et al. Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine: a comprehensive review. Adv Ther 2016; 33:1094–104.
11. Doeling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103–8.
12. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44(Suppl 1):S1–26.
13. Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Prevention of herpes
zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1–30; quiz CE2–4.

14. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340–6.

15. ZOSTAVAX® (Zoster Vaccine Live) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc., 2018.

16. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347:26–34.

17. Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis 2013; 208:1375–85.

18. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176:578–85.

19. Eberhardson M, Hall S, Papp KA, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial. Clin Infect Dis 2017; 65:1174–82.

20. Parrino J, McNeil SA, Lawrence SJ, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine 2017; 35:1764–9.

21. Keller PM, Lonergan K, Neff BJ, et al. Purification of individual varicella-zoster virus (VZV) glycoproteins gpl, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 1986; 14:177–88.

22. Smith IG, Liu X, Kaufhold RM, et al. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8:871–9.

23. Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya: Indian J Stat (Ser B) 2000; 62:134–48.

24. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271–84.

25. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012; 54:922–8.

26. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825–35.

27. Levin MJ, Schmader KE, Gnann JW, et al. Varicella-zoster virus-specific antibody responses in 50–59 year-old recipients of zoster vaccine. J Infect Dis 2013; 208:1386–90.

28. Arvin AM. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6:219–30.

29. Karras NA, Weeres M, Sessions W, et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant 2013; 19:109–16.

30. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008; 42:637–41.

31. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008; 86:257–63.